{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:28:33Z","timestamp":1782509313888,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["ARUK\u2010PPG2017A\u201019"],"award-info":[{"award-number":["ARUK\u2010PPG2017A\u201019"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203139\/Z\/16\/Z"],"award-info":[{"award-number":["203139\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Frontotemporal lobar degeneration (FTLD) is a neuropathological construct with multiple clinical presentations, including the behavioural variant of frontotemporal dementia (bvFTD), primary progressive aphasia\u2014both non-fluent variant (nfvPPA) and semantic variant (svPPA)\u2014progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), characterised by the deposition of abnormal tau protein in the brain. A major challenge for treating FTLD is early diagnosis and accurate discrimination among different syndromes. The main goal here was to investigate the cortical architecture of FTLD syndromes using cortical diffusion tensor imaging (DTI) analysis and to test its power to discriminate between different clinical presentations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 271 individuals were included in the study: 87 healthy subjects (HS), 31 semantic variant primary progressive aphasia (svPPA), 37 behavioural variant (bvFTD), 30 non-fluent\/agrammatic variant primary progressive aphasia (nfvPPA), 47 PSP Richardson\u2019s syndrome (PSP-RS) and 39 CBS cases. 3T MRI T1-weighted images and DTI scans were analysed to extract three cortical DTI derived measures (AngleR, PerpPD and ParlPD) and mean diffusivity (MD), as well as standard volumetric measurements. Whole brain and regional data were extracted. Linear discriminant analysis was used to assess the group discrimination capability of volumetric and DTI measures to differentiate the FTLD syndromes. In addition, in order to further investigate differential diagnosis in CBS and PSP-RS, a subgroup of subjects with autopsy confirmation in the training cohort was used to select features which were then tested in the test cohort.<\/jats:p>\n                <jats:p>Three different challenges were explored: a binary classification (controls vs all patients), a multiclass classification (HS vs bvFTD vs svPPA vs nfvPPA vs CBS vs PSP-RS) and an additional binary classification to differentiate CBS and PSP-RS using features selected in an autopsy confirmed subcohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Linear discriminant analysis revealed that PerpPD was the best feature to distinguish between controls and all patients (ACC 86%). PerpPD regional values were able to classify correctly the different FTLD syndromes with an accuracy of 85.6%. The PerpPD and volumetric values selected to differentiate CBS and PSP-RS patients showed a classification accuracy of 85.2%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>(I) PerpPD achieved the highest classification power for differentiating healthy controls and FTLD syndromes and FTLD syndromes among themselves. <jats:bold>(<\/jats:bold>II) PerpPD regional values could provide an additional marker to differentiate FTD, PSP-RS and CBS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00914-4","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:13:55Z","timestamp":1634919235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intracortical diffusion tensor imaging signature of microstructural changes in frontotemporal lobar degeneration"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-9167","authenticated-orcid":false,"given":"Mario","family":"Torso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard R.","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Frontotemporal Lobar Degeneration Neuroimaging Initiative and the 4-Repeat Tau Neuroimaging Initiative (4RTNI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"914_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:9.","journal-title":"Brain"},{"key":"914_CR2","first-page":"76(11)","volume":"2011","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;2011:76(11).","journal-title":"Neurology."},{"key":"914_CR3","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang A E, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Movement Disorders. 2017;32(6)."},{"key":"914_CR4","doi-asserted-by":"crossref","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1).","DOI":"10.1212\/WNL.47.1.1"},{"key":"914_CR5","doi-asserted-by":"publisher","first-page":"80(5)","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"29","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;29:80(5). https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology."},{"issue":"4","key":"914_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2015","unstructured":"Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta neuropathologica. 2015;129(4):469\u201391.","journal-title":"Acta neuropathologica."},{"key":"914_CR7","volume-title":"Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations","author":"IR Mackenzie","year":"2009","unstructured":"Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. 2009"},{"key":"914_CR8","doi-asserted-by":"publisher","unstructured":"Kovacs GG. Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015 Feb;41(1). doi: https:\/\/doi.org\/10.1111\/nan.12208.","DOI":"10.1111\/nan.12208"},{"key":"914_CR9","doi-asserted-by":"publisher","first-page":"386(10004)","DOI":"10.1016\/S0140-6736(15)00461-4","volume":"24","author":"J Bang","year":"2015","unstructured":"Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;24:386(10004). https:\/\/doi.org\/10.1016\/S0140-6736(15)00461-4.","journal-title":"Lancet."},{"key":"914_CR10","doi-asserted-by":"publisher","first-page":"87(12)","DOI":"10.1212\/WNL.0000000000003119","volume":"20","author":"CT McMillan","year":"2016","unstructured":"McMillan CT, Boyd C, Gross RG, Weinstein J, Firn K, Toledo JB, et al. Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology. 2016;20:87(12). https:\/\/doi.org\/10.1212\/WNL.0000000000003119.","journal-title":"Neurology."},{"key":"914_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41531-017-0012-6","volume":"3","author":"F Albrecht","year":"2017","unstructured":"Albrecht F, Bisenius S, Morales Schaack R, Neumann J, Schroeter ML. Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta-analyses. NPJ Parkinsons Dis. 2017;3:12. https:\/\/doi.org\/10.1038\/s41531-017-0012-6.","journal-title":"NPJ Parkinsons Dis."},{"key":"914_CR12","doi-asserted-by":"publisher","first-page":"3(3)","DOI":"10.2463\/mrms.3.125","volume":"15","author":"M Adachi","year":"2004","unstructured":"Adachi M, Kawanami T, Ohshima H, Sugai Y, Hosoya T. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci. 2004;15:3(3). https:\/\/doi.org\/10.2463\/mrms.3.125.","journal-title":"Magn Reson Med Sci."},{"key":"914_CR13","doi-asserted-by":"publisher","unstructured":"Massey LA, Micallef C, Paviour DC, O'Sullivan SS, Ling H, Williams DR, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14). doi: https:\/\/doi.org\/10.1002\/mds.24968.","DOI":"10.1002\/mds.24968"},{"key":"914_CR14","doi-asserted-by":"publisher","first-page":"25(14)","DOI":"10.1002\/mds.23351","volume":"30","author":"A Hussl","year":"2010","unstructured":"Hussl A, Mahlknecht P, Scherfler C, Esterhammer R, Schocke M, Poewe W, et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord. 2010;30:25(14). https:\/\/doi.org\/10.1002\/mds.23351.","journal-title":"Mov Disord."},{"key":"914_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nicl.2016.05.016","volume":"30","author":"S Zanigni","year":"2016","unstructured":"Zanigni S, Calandra-Buonaura G, Manners DN, Testa C, Gibertoni D, Evangelisti S, et al. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease. Neuroimage Clin. 2016;30:11. https:\/\/doi.org\/10.1016\/j.nicl.2016.05.016.","journal-title":"Neuroimage Clin."},{"key":"914_CR16","doi-asserted-by":"publisher","unstructured":"Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;31;11(1):13. doi: https:\/\/doi.org\/10.1186\/s13195-019-0470-7.","DOI":"10.1186\/s13195-019-0470-7"},{"key":"914_CR17","doi-asserted-by":"publisher","unstructured":"Chance SA, Clover L, Cousijn H, Currah L, Pettingill R, Esiri MM. Microanatomical correlates of cognitive ability and decline: normal ageing, MCI, and Alzheimer's disease. Cereb Cortex. 2011;21(8). doi: https:\/\/doi.org\/10.1093\/cercor\/bhq264.","DOI":"10.1093\/cercor\/bhq264"},{"key":"914_CR18","doi-asserted-by":"publisher","unstructured":"van Veluw SJ, Sawyer EK, Clover L, Cousijn H, De Jager C, Esiri MM, Chance SA. Prefrontal cortex cytoarchitecture in normal aging and Alzheimer's disease: a relationship with IQ. Brain Struct Funct. 2012;217(4). doi: https:\/\/doi.org\/10.1007\/s00429-012-0381-x.","DOI":"10.1007\/s00429-012-0381-x"},{"key":"914_CR19","doi-asserted-by":"publisher","unstructured":"Chance SA, Casanova MF, Switala AE, Crow TJ, Esiri MM. Minicolumn thinning in temporal lobe association cortex but not primary auditory cortex in normal human ageing. Acta Neuropathol. 2006;111(5). doi: https:\/\/doi.org\/10.1007\/s00401-005-0014-z.","DOI":"10.1007\/s00401-005-0014-z"},{"key":"914_CR20","doi-asserted-by":"publisher","unstructured":"Torso M, Bozzali M, Zamboni G, Jenkinson M, Chance SA; Alzheimers Disease Neuroimage Initiative. Detection of Alzheimer's Disease using cortical diffusion tensor imaging. Hum Brain Mapp. 2021;42(4). doi: https:\/\/doi.org\/10.1002\/hbm.25271.","DOI":"10.1002\/hbm.25271"},{"key":"914_CR21","doi-asserted-by":"publisher","unstructured":"McKavanagh R, Torso M, Jenkinson M, Kolasinski J, Stagg CJ, Esiri MM, et al. Relating diffusion tensor imaging measurements to microstructural quantities in the cerebral cortex in multiple sclerosis. Hum Brain Mapp. 2019;40(15). doi: https:\/\/doi.org\/10.1002\/hbm.24711.","DOI":"10.1002\/hbm.24711"},{"key":"914_CR22","doi-asserted-by":"publisher","unstructured":"Ill\u00e1n-Gala I, Montal V, Borrego-\u00c9cija S, Vilaplana E, Pegueroles J, Alcolea D, et al. Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain. 2019;142(4). doi: https:\/\/doi.org\/10.1093\/brain\/awz031.","DOI":"10.1093\/brain\/awz031"},{"key":"914_CR23","doi-asserted-by":"publisher","unstructured":"Torso M, Ahmed S, Butler C, Zamboni G, Jenkinson M, Chance S. Cortical diffusivity investigation in posterior cortical atrophy and typical Alzheimer's disease. J Neurol. 2021;268(1). doi: https:\/\/doi.org\/10.1007\/s00415-020-10109-w.","DOI":"10.1007\/s00415-020-10109-w"},{"issue":"1","key":"914_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13195-020-00679-2","volume":"12","author":"PSJ Weston","year":"2020","unstructured":"Weston PSJ, Poole T, Nicholas JM, Toussaint N, Simpson IJA, Modat M, et al. Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. Alzheimers Res Ther. 2020;12(1):112. https:\/\/doi.org\/10.1186\/s13195-020-00679-2.","journal-title":"Alzheimers Res Ther."},{"key":"914_CR25","doi-asserted-by":"publisher","unstructured":"Vilaplana E, Rodriguez-Vieitez E, Ferreira D, Montal V, Almkvist O, Wall A, et al. Cortical microstructural correlates of astrocytosis in autosomal dominant Alzheimer disease. Neurology. 2020; https:\/\/doi.org\/10.1212\/WNL.","DOI":"10.1212\/WNL"},{"key":"914_CR26","doi-asserted-by":"crossref","unstructured":"Alshikho MJ, Z\u00fcrcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O, et al. Integrated magnetic resonance imaging and [11 C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018;83.","DOI":"10.1002\/ana.25251"},{"key":"914_CR27","doi-asserted-by":"publisher","unstructured":"Dickstein DL, De Gasperi R, Gama Sosa MA, Perez-Garcia G, Short JA, Sosa H, et al. Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Mol Psychiatry. 2020. https:\/\/doi.org\/10.1038\/s41380-020-0674-z.","DOI":"10.1038\/s41380-020-0674-z"},{"issue":"1","key":"914_CR28","doi-asserted-by":"publisher","first-page":"11237","DOI":"10.1038\/s41598-020-68118-8","volume":"10","author":"M Torso","year":"2020","unstructured":"Torso M, Bozzali M, Cercignani M, Jenkinson M, Chance SA. Using diffusion tensor imaging to detect cortical changes in fronto-temporal dementia subtypes. Sci Rep. 2020 Jul 8;10(1):11237. https:\/\/doi.org\/10.1038\/s41598-020-68118-8.","journal-title":"Sci Rep."},{"key":"914_CR29","doi-asserted-by":"publisher","unstructured":"Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol. 2004;3(12). doi: https:\/\/doi.org\/10.1016\/S1474-4422(04)00936-6.","DOI":"10.1016\/S1474-4422(04)00936-6"},{"key":"914_CR30","doi-asserted-by":"publisher","unstructured":"Jabbari E, Holland N, Chelban V, Jones PS, Lamb R, Rawlinson C, et al. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurol. 2020;77(3). doi: https:\/\/doi.org\/10.1001\/jamaneurol.2019.4347.","DOI":"10.1001\/jamaneurol.2019.4347"},{"key":"914_CR31","doi-asserted-by":"publisher","unstructured":"Iglesias JE, Van Leemput K, Bhatt P, Casillas C, Dutt S, Schuff N, et al. Alzheimer's Disease Neuroimaging Initiative. Bayesian segmentation of brainstem structures in MRI. Neuroimage. 2015 Jun;113. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.02.065.","DOI":"10.1016\/j.neuroimage.2015.02.065"},{"key":"914_CR32","doi-asserted-by":"publisher","unstructured":"Chance SA, Torso M, Jenkinson M. Cortical disarray measurement using diffusion MRI correlates with Braak staging and improves Amyloid PET prediction of AD progression. Alzheimers & Dementia July 24, 2018: Alzheimer's Association International Conference: P3-388: Poster Presentations https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1750).","DOI":"10.1016\/j.jalz.2018.06.1750"},{"key":"914_CR33","volume-title":"Die cytoarchitektonik der hirnrinde des erwachsenen menschen","author":"CF von Economo","year":"1925","unstructured":"von Economo CF and Koskinas GN. (1925). Die cytoarchitektonik der hirnrinde des erwachsenen menschen. J. Springer."},{"key":"914_CR34","doi-asserted-by":"crossref","unstructured":"Benjamini Y, & Yekutieli D. The control of the false discovery rate in multiple testing under dependency. The Annals of Statistics 2001; 29(4).","DOI":"10.1214\/aos\/1013699998"},{"key":"914_CR35","doi-asserted-by":"publisher","unstructured":"Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3). doi: https:\/\/doi.org\/10.1007\/s12031-011-9589-0.","DOI":"10.1007\/s12031-011-9589-0"},{"key":"914_CR36","doi-asserted-by":"publisher","unstructured":"Levin J, Kurz A, Arzberger T, Giese A, H\u00f6glinger GU. The Differential Diagnosis and Treatment of Atypical Parkinsonism. Dtsch Arztebl Int. 2016;113(5). doi: https:\/\/doi.org\/10.3238\/arztebl.2016.0061.","DOI":"10.3238\/arztebl.2016.0061"},{"key":"914_CR37","doi-asserted-by":"crossref","unstructured":"Giannini LA, Peterson C, Ohm D, Xie SX, McMillan CT, Raskovsky K, et al. Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta neuropathologica communications. 2021;9(1).","DOI":"10.1186\/s40478-021-01129-2"},{"key":"914_CR38","doi-asserted-by":"publisher","unstructured":"Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6). doi: https:\/\/doi.org\/10.1212\/wnl.51.6.1546.","DOI":"10.1212\/wnl.51.6.1546"},{"key":"914_CR39","doi-asserted-by":"publisher","unstructured":"Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol. 2006;63(1). doi: https:\/\/doi.org\/10.1001\/archneur.63.1.81.","DOI":"10.1001\/archneur.63.1.81"},{"key":"914_CR40","doi-asserted-by":"publisher","unstructured":"Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, et al.; Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11). doi: https:\/\/doi.org\/10.1093\/jnen\/61.11.935.","DOI":"10.1093\/jnen\/61.11.935"},{"key":"914_CR41","doi-asserted-by":"publisher","DOI":"10.1201\/b22602","volume-title":"Greenfield's Neuropathology, 2-Volume Set","author":"S Love","year":"2008","unstructured":"Love S, Louis D, Ellison DW. Greenfield's Neuropathology, 2-Volume Set: CRC Press; 2008."},{"key":"914_CR42","doi-asserted-by":"publisher","unstructured":"Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain. 2007;130(Pt 6). doi: https:\/\/doi.org\/10.1093\/brain\/awm104.","DOI":"10.1093\/brain\/awm104"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00914-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:19:47Z","timestamp":1634919587000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00914-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00914-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research involves only previously collected and fully anonymised data so further ethical approval was not required ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT, MJ and SAC have submitted patent applications related to diffusion MRI analysis. SAC is a co-founder of a company, Oxford Brain Diagnostics. MJ is co-founder of a company, Oxford Brain Diagnostics, from which he has received no funding for the research or preparation of this manuscript. MT and GRR are currently employed at a company, Oxford Brain Diagnostics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}